OPK Stock Overview
OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally.
Snowflake Score | |
---|---|
Valuation | 4/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 3/6 |
Dividends | 0/6 |
OPKO Health, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$1.20 |
52 Week High | US$2.24 |
52 Week Low | US$0.85 |
Beta | 1.8 |
1 Month Change | 21.77% |
3 Month Change | -20.53% |
1 Year Change | -17.81% |
3 Year Change | -72.60% |
5 Year Change | -54.02% |
Change since IPO | -73.33% |
Recent News & Updates
Recent updates
OPKO Health, Inc. (NASDAQ:OPK) Not Flying Under The Radar
Dec 30Is OPKO Health (NASDAQ:OPK) A Risky Investment?
Oct 03OPKO Health, Inc.'s (NASDAQ:OPK) 28% Share Price Surge Not Quite Adding Up
Jul 24Would OPKO Health (NASDAQ:OPK) Be Better Off With Less Debt?
Jun 07Is OPKO Health (NASDAQ:OPK) Using Too Much Debt?
Jan 04OPKO Health: Assessing If Significant Potential Can Be Realized
Sep 15OPKO Health (NASDAQ:OPK) Is Carrying A Fair Bit Of Debt
Sep 05OPKO Health: 14%+ Short Interest Means More Volatility Over The Near Term
Jun 21OPKO Health (NASDAQ:OPK) Is Carrying A Fair Bit Of Debt
Apr 29OPKO Health: A Great Long-Term Investment In Health
Apr 05OPKO Health Is Risky But Might Make You Money
Mar 29Analysts Have Just Cut Their OPKO Health, Inc. (NASDAQ:OPK) Revenue Estimates By 14%
Feb 27OPKO Health (NASDAQ:OPK) Has A Pretty Healthy Balance Sheet
Jan 12OPKO Health: Undervalued Opportunity
Dec 23OPKO Health: Bullish Case Still Intact
Dec 15We Think OPKO Health (NASDAQ:OPK) Can Stay On Top Of Its Debt
Sep 27OPKO Health: A Defensive, Long-Term Holding
Sep 19Shareholder Returns
OPK | US Healthcare | US Market | |
---|---|---|---|
7D | 24.4% | 1.1% | 0.2% |
1Y | -17.8% | 9.4% | 28.1% |
Return vs Industry: OPK underperformed the US Healthcare industry which returned 9.4% over the past year.
Return vs Market: OPK underperformed the US Market which returned 28.1% over the past year.
Price Volatility
OPK volatility | |
---|---|
OPK Average Weekly Movement | 14.1% |
Healthcare Industry Average Movement | 7.4% |
Market Average Movement | 6.1% |
10% most volatile stocks in US Market | 16.8% |
10% least volatile stocks in US Market | 3.0% |
Stable Share Price: OPK's share price has been volatile over the past 3 months.
Volatility Over Time: OPK's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1991 | 3,930 | Phil Frost | https://www.opko.com |
OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company’s Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women’s health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test. Its Pharmaceutical segment offers Rayaldee to treat secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, and vitamin D insufficiency.
OPKO Health, Inc. Fundamentals Summary
OPK fundamental statistics | |
---|---|
Market cap | US$836.39m |
Earnings (TTM) | -US$188.86m |
Revenue (TTM) | US$863.50m |
1.0x
P/S Ratio-4.4x
P/E RatioIs OPK overvalued?
See Fair Value and valuation analysisEarnings & Revenue
OPK income statement (TTM) | |
---|---|
Revenue | US$863.50m |
Cost of Revenue | US$634.96m |
Gross Profit | US$228.53m |
Other Expenses | US$417.40m |
Earnings | -US$188.86m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -0.27 |
Gross Margin | 26.47% |
Net Profit Margin | -21.87% |
Debt/Equity Ratio | 17.9% |
How did OPK perform over the long term?
See historical performance and comparison